Thyrocare Technologies THYROCARE
Low-cost, high-volume pathology lab with a central-lab model and franchise collection network; majority-owned by PharmEasy's parent
Mapped in 1 theme: Hospitals & Healthcare.
Where Thyrocare Technologies sits in the supply chain
Thyrocare Technologies appears in 1 supply-chain layer in one theme, Hospitals & Healthcare.
Hospitals & Healthcare › Pathology labs
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 589 | 527 | 572 | 687 | 829 |
| Net profit | 176 | 64 | 69 | 91 | 163 |
Latest-year revenue ₹829 Cr (FY26, company-wide).
Strengths
- Lowest-cost processing in the industry from a central automated lab
- Wellness and preventive packages sold in bulk
Risks
- Majority owner API Holdings (PharmEasy) is loss-making - group risk
- Low prices mean thin room for further cuts
Common questions
What does Thyrocare Technologies do?
Low-cost, high-volume pathology lab with a central-lab model and franchise collection network; majority-owned by PharmEasy's parent.
Where does Thyrocare Technologies sit in the supply chain?
Thyrocare Technologies (NSE: THYROCARE) is mapped in 1 supply-chain layer: Pathology labs (Hospitals & Healthcare).
Who are Thyrocare Technologies' peers?
In the Pathology labs layer of Hospitals & Healthcare: Dr Lal PathLabs, Metropolis Healthcare, Vijaya Diagnostic Centre, Fortis Healthcare and Neuberg Diagnostics (not NSE-listed).
What is Thyrocare Technologies' market cap and valuation?
As of 6 Nov 2026: market cap ₹7,841 Cr, P/E 44.8x, ROCE 35.4%, ROE 28.4%, dividend yield 1.89%.